Becton Dickinson Announces Reverse Morris Trust with Waters

Becton Dickinson ( (BDX) ) has issued an update.

On July 13, 2025, Becton, Dickinson and Company announced a Reverse Morris Trust transaction with Waters Corporation, combining its Biosciences and Diagnostic Solutions business with Waters. This strategic move will result in BD receiving approximately $4 billion in cash and its shareholders owning 39.2% of Waters’ common stock. The transaction involves several steps, including the separation of BD’s Biosciences and Diagnostic Solutions Business into a new entity, SpinCo, which will then merge with a subsidiary of Waters. This merger has been approved by both companies’ boards and is expected to enhance BD’s financial position and market influence.

The most recent analyst rating on (BDX) stock is a Buy with a $280.00 price target. To see the full list of analyst forecasts on Becton Dickinson stock, see the BDX Stock Forecast page.

Spark’s Take on BDX Stock

According to Spark, TipRanks’ AI Analyst, BDX is a Outperform.

Becton Dickinson scores well due to strong financial performance and a major strategic merger, which are significant positives. However, technical indicators and valuation metrics suggest caution, while earnings call insights reveal challenges in certain segments and geographic areas that could impact short-term growth.

To see Spark’s full report on BDX stock, click here.

More about Becton Dickinson

Becton, Dickinson and Company (BD) is a New Jersey-based corporation operating in the biosciences and diagnostic solutions industry. The company focuses on providing medical technology and solutions that improve medical research and diagnostics.

Average Trading Volume: 3,069,998

Technical Sentiment Signal: Sell

Current Market Cap: $50.43B

Find detailed analytics on BDX stock on TipRanks’ Stock Analysis page.